Thailand Neurology Clinical Trials Market Report 2022 to 2030

Thailand Neurology Clinical Trials Market Analysis

$ 3999

The Thailand Neurology Clinical Trials market is projected to grow from $6.28 Mn in 2022 to $9.88 Mn by 2030, registering a CAGR of 5.84% during the forecast period of 2022 - 2030. The market will be driven by the country's favourable regulatory environment, big patient pool, and highly qualified medical professionals. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Pfizer Inc. & Siam Bioscience Co., Ltd.

ID: IN10THCT005 CATEGORY: Clinical Trials GEOGRAPHY: Thailand AUTHOR: Vidhi Upadhyay

Buy Now

Thailand Neurology Clinical Trials Market Executive Summary

The Thailand Neurology Clinical Trials market is projected to grow from $6.28 Mn in 2022 to $9.88 Mn by 2030, registering a CAGR of 5.84% during the forecast period of 2022 - 2030. Thailand is rising as a clinical trial leader due to its world-class infrastructure, universal healthcare system, and supportive state regulations for the clinical research sector. According to a Deloitte Access Economics analysis, roughly USD 320 million was spent on Thai clinical trials in 2015, with Phase III research accounting for 75% of that amount. In Thailand, the incidence of dementia ranges from 1.8 to 10.2% in people aged 55 and above, while another research from Mahidol University found that dementia is only approximately 1% in those aged 60 to 69, but it rises to more than 30% in people aged 90 and more.

Thailand has a huge population of people suffering from neurological illnesses, providing a big patient pool for clinical studies. Stroke, epilepsy, and Parkinson's disease are among the most frequent neurological illnesses in Thailand. Numerous global pharmaceutical corporations and clinical research organisations, including Pfizer, Novartis, and GSK, have undertaken neurological clinical studies in Thailand. Moreover, some local companies and research institutes, such as Siriraj Hospital and Mahidol University in Thailand, are actively interested in neurology clinical trials.

The Thai Food and Drug Administration (TFDA) has put in place laws and procedures to guarantee that clinical trials adhere to worldwide standards, which has helped to attract pharmaceutical businesses and researchers to the country. Thailand has also formed the National Science and Technology Development Agency (NSTDA) to promote and assist the country's research and development operations. Overall, the Thai neurology clinical trials market is likely to expand in the future years, owing to the country's favourable regulatory environment, big patient pool, and highly qualified medical professionals.

Thailand Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The Thai Food and Drug Administration (TFDA) has put in place laws and procedures to guarantee that clinical trials adhere to worldwide standards, which has helped to attract pharmaceutical businesses and researchers to the country. Thailand has a huge population of people suffering from neurological illnesses, providing a big patient pool for clinical studies. Thailand offers well-equipped healthcare facilities as well as highly experienced medical professionals, making it an appealing destination for clinical trials. The Thai government has made major expenditures in R&D operations, notably in neurology, which has aided in the expansion of clinical trials in the nation.

Market Restraints

Thailand faces competition from other nations with big patient populations and favourable regulatory frameworks for clinical trials, such as India and China. Although Thailand has well-equipped healthcare facilities, access to new technology necessary for particular kinds of neurology clinical trials may be restricted. That is the major language spoken in Thailand, which may provide a challenge for non-Thai-speaking academics and pharmaceutical firms conducting clinical studies there. Patient recruitment may be difficult in certain circumstances, notably in uncommon neurological illnesses with small patient populations.

Competitive Landscape

Key Players

Novartis International AG
Pfizer Inc.
Merck & Co., Inc.
Sanofi S.A.
GlaxoSmithKline plc (GSK)
AbbVie Inc.
Biogen Inc.
Siam Bioscience Co., Ltd. (THA)
Chao Phya Abhaibhubejhr Hospital and Thai Traditional Medicine Development Center (THA)
Mega Lifesciences Public Company Limited (THA)
The Government Pharmaceutical Organization (THA)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.